Hoge Stephen, president of Moderna (MRNA), has been a consistent seller of company stock over the past year, with SEC Form 4 filings showing 42 total transactions and no open-market purchases. His selling bias is unambiguous: total sales reached $16.7 million against zero buy value, and the three most recent trades—all in July 2026—were open-market sales totaling roughly $3.6 million. The pattern is one of steady liquidation, with sales occurring monthly from May through July 2026, each paired with option exercises (code M) that supplied the shares being sold.
The transaction structure reveals that Stephen's sales are largely mechanical, tied to pre-scheduled option exercises rather than discretionary timing. On July 15, 2026, for example, he exercised options valued at $308,506 and $712,877, then immediately sold shares worth $3.6 million. Similar pairings occurred on June 15 and May 15, with sales of $2.7 million and $2.6 million respectively. The remaining filings are dominated by code F transactions—shares withheld to cover tax obligations on vesting awards—which are automatic and carry no directional signal. The only code A grants occurred in March 2026, valued at zero, indicating compensation awards rather than cash purchases.
Across the entire filing history, Stephen's activity is concentrated exclusively in MRNA, with no diversification into other tickers. The absence of any code P purchases—the only transaction type showing conviction—reinforces a posture of ongoing distribution. While the option exercises and tax withholdings are routine, the consistent monthly sales of $2.5–$3.6 million suggest a deliberate, sustained reduction of his equity position in Moderna.
AI-assisted summary